



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tregalizumab

Cat. No.:	HY-P99327
CAS No.:	1207446-68-1
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies ^{[1][2][3]} .									
IC₅₀ & Target	CD4 ^{[1][2][3]} .									
In Vitro	<p>Tregalizumab is able to activate the suppressive capacity of regulatory T cells^[1].</p> <p>Tregalizumab reduces proliferation and cytokine secretion when isolated PBMCs are stimulated with tetanus toxoid in a dose-dependent manner^[1].</p> <p>Tregalizumab (0-30 µg/mL; 18 h) treatment of PBMC induces CD4 down-modulation of T cells^[2].</p> <p>Tregalizumab primarily induces CD4 down-modulation at inflammatory sites^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>PBMC cells</td> </tr> <tr> <td>Concentration:</td> <td>0-30 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>18 h</td> </tr> <tr> <td>Result:</td> <td>Induced CD4 down-modulation of T cells.</td> </tr> </table>		Cell Line:	PBMC cells	Concentration:	0-30 µg/mL	Incubation Time:	18 h	Result:	Induced CD4 down-modulation of T cells.
Cell Line:	PBMC cells									
Concentration:	0-30 µg/mL									
Incubation Time:	18 h									
Result:	Induced CD4 down-modulation of T cells.									

REFERENCES

- [1]. König M, et al. Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. *Front Immunol.* 2016 Jan 25;7:11.
- [2]. Vogel S, et al. Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells. *Sci Rep.* 2015 Dec 16;5:18308.
- [3]. Helling B, et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. *Immunol Cell Biol.* 2015 Apr;93(4):396-405.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA